Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053306 · ClinicalTrials.gov registry record · Phase 1
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
A Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT07053306: Recruiting Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
NCT07053306 is a Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 29 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053306, a Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
Primary Outcome
Measurement of ketone body turnover rate during the baseline state and 240-300-minute time period, before and after Empagliflozin administration.
Conditions Studied
Interventions
- DRUG Empagliflozin 25 MG
Study Locations (1)
Texas
- Texas Diabetes Institute/UH - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
What NCT07053306 shows while recruiting
NCT07053306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Empagliflozin 25 MG is the first listed.
NCT07053306 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07053306 about?
NCT07053306 is a clinical study titled "SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia". To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
What is the current status of trial NCT07053306?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2025-04-29. Estimated completion is 2027-06-30.
What conditions does trial NCT07053306 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07053306?
The interventions under investigation include: Empagliflozin 25 MG (DRUG).
Who is sponsoring clinical trial NCT07053306?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053306 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053306's enrollment target sits among peer trials
29 272nd of 327 higher than 56 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
SGLT2i, Pioglitazone, and Ketone Production in T2D
RECRUITING · Phase 1
-
A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers
RECRUITING · Phase 1
-
THC Effects on Glucose in Type 2 Diabetes
RECRUITING · Phase 1
-
Polypill for Prevention of Cardiomyopathy
RECRUITING · Phase 1
-
SGLTi, Hepatic Glucose Production and Ketogenesis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI